<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pharmacol</journal-id><journal-title>BMC Pharmacology</journal-title><issn pub-type="epub">1471-2210</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15296516</article-id><article-id pub-id-type="pmc">PMC514535</article-id><article-id pub-id-type="publisher-id">1471-2210-4-15</article-id><article-id pub-id-type="doi">10.1186/1471-2210-4-15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Proteasome inhibitors: Their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Levine</surname><given-names>Lawrence</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>llevine@brandeis.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biochemistry, Brandeis University Waltham, MA 02454, USA</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>5</day><month>8</month><year>2004</year></pub-date><volume>4</volume><fpage>15</fpage><lpage>15</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2210/4/15"/><history><date date-type="received"><day>22</day><month>3</month><year>2004</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Levine; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Levine; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Levine
               Lawrence
               
               llevine@brandeis.edu
            </dc:author><dc:title>
            Proteasome inhibitors: Their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>BMC Pharmacology 4(1): 15-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2210(2004)4:1&#x0003c;15&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2210</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>I have postulated that arachidonic acid release from rat liver cells is associated with cancer chemoprevention. Since it has been reported that inhibition of proteasome activities may prevent cancer, the effects of proteasome inhibitors on arachidonic acid release from cells and on prostaglandin I<sub>2 </sub>production in rat liver cells were studied.</p></sec><sec><title>Results</title><p>The proteasome inhibitors, epoxomicin, lactacystin and carbobenzoxy-leucyl-leucyl-leucinal, stimulate the release of arachidonic acid from rat glial, human colon carcinoma, human breast carcinoma and the rat liver cells. They also stimulate basal and induced prostacycin production in the rat liver cells. The stimulated arachidonic acid release and basal prostaglandin I<sub>2 </sub>production in rat liver cells is inhibited by actinomycin D.</p></sec><sec><title>Conclusions</title><p>Stimulation of arachidonic acid release and arachidonic acid metabolism may be associated with some of the biologic effects observed after proteasome inhibition, e.g. prevention of tumor growth, induction of apoptosis, stimulation of bone formation.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The proteasome degrades many cellular proteins, several with regulatory functions. It is not surprising that proteasome inhibitors affect many biologic processes [<xref ref-type="bibr" rid="B1">1</xref>] including prevention of cancer [<xref ref-type="bibr" rid="B2">2</xref>]. The effect of proteasome inhibition on cell growth and possible cancer chemoprevention has been reviewed by Adams [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Epoxomicin, an &#x003b1;'-&#x003b2;'-epoxyketone, appears to be the most selective proteasome inhibitor. Based on its anti-tumor activity, this product was originally isolated from an actinomycetes strain C-996-17 [<xref ref-type="bibr" rid="B4">4</xref>]. It inhibits the chymotrypsin-like activity (cleavage after large hydrophobic residues), trypsin-like activity (cleavage after basic residues) and peptidyl-glutamyl peptide hydrolyzing (PGPH) activity (cleavage after acidic residues) of proteasomes. Activities of the Ca<sup>++</sup>-dependent proteases, calpain, papain, chymotrypsin, trypsin and cathepsin are not affected by epoxomicin even at a 50 &#x003bc;M concentration [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>The &#x003b2;-lactone, lactacystin, is relatively selective but can inhibit cathepsin A [<xref ref-type="bibr" rid="B6">6</xref>]. Peptide aldehydes, in addition to inhibiting proteasome activity, can also inhibit lysosomal and Ca<sup>++</sup>-activated proteases [<xref ref-type="bibr" rid="B7">7</xref>]. The peptides containing the carboxyvinylsulfone moiety inhibit cysteine proteases [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>I have shown that inhibition of proteolysis by phenylmethylsulphonyl fluoride, the peptide aldehydes carbobenzoxy-leucyl-leucyl-norvalinal and carbobenzoxy-leucyl-leucyl-leucinal (ZLLL) and lactacystin stimulate induced prostaglandin (PGI<sub>2</sub>) production in rat liver cells [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Lactacystin stimulates arachidonic acid (AA) release from these cells [<xref ref-type="bibr" rid="B11">11</xref>]. Others have reported that proteasome inhibition up-regulates cyclooxygenase-2 (COX-2) and stimulates PGE<sub>2 </sub>production in neuronal cells [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>In this report, evidence is presented that proteasome inhibitors stimulate PGI<sub>2 </sub>production by rat liver cells as well as the release of AA from rat liver, rat glial, human colon carcinoma and human breast carcinoma cells in culture. The stimulation of AA release from rat liver cells is partially inhibited by preincubation of the cells with actinomycin D.</p></sec><sec><title>Results and Discussion</title><p>Of the cells examined (C-9 rat liver, C-6 rat glial, HT-29 human colon carcinoma and BT-20 human breast carcinoma) the prostanoid metabolic profile has been described only for C-9 rat liver cells (95% is PGI<sub>2 </sub>and less than 5% is PGE<sub>2 </sub>and PGF<sub>2&#x003b1;</sub>) [<xref ref-type="bibr" rid="B13">13</xref>]. At the low cell densities used in this study, only PGI<sub>2</sub>, the main product of COX-mediated synthesis, can be quantitatively estimated. The rat liver cells express COX-2 both constitutively and after induction [<xref ref-type="bibr" rid="B14">14</xref>]. The effect of time on basal and 12-0-tetradecanoylphorbol-13-acetate (TPA) induced PGI<sub>2 </sub>synthesis during incubation of cells with epoxomicin is shown in Fig. <xref ref-type="fig" rid="F1">1</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Time-course of (A) basal and (B) TPA-induced 6-keto-PGF<sub>1&#x003b1; </sub>production during incubation with 1.2 &#x003bc;M epoxomicin. In (B) 16.7 nM TPA was used. Analyses were performed with duplicate and triplicate dishes. Mean values are shown.</p></caption><graphic xlink:href="1471-2210-4-15-1"/></fig><p>The stimulation of basal PGI<sub>2 </sub>production by epoxomicin and TPA-induced PGI<sub>2 </sub>production by epoxomicin and lactacystin as a function of dose is shown in Fig. <xref ref-type="fig" rid="F2">2</xref>. As little as 0.3 &#x003bc;M epoxomicin stimulates TPA-induced PGI<sub>2 </sub>production significantly (Fig. <xref ref-type="fig" rid="F2">2-B</xref>). It is 10 to 15 times more effective than lactacystin (compare Fig. <xref ref-type="fig" rid="F2">2-B</xref> and <xref ref-type="fig" rid="F2">2-C</xref>). Using purified bovine erythrocyte proteasomes, epoxomicin inhibits the chymotrypsin-like activity, about 4 to 5 times more effectively than does <italic>clasto</italic>-lactacystin &#x003b2;-lactone, the derivative of lactacystin [<xref ref-type="bibr" rid="B5">5</xref>]. They are almost equally effective on inhibiting the trypsin-like and PGPH-like activities [<xref ref-type="bibr" rid="B5">5</xref>]. Assuming that epoxomicin and lactacystin have equal access to the proteasome and that proteasome activity is regulating COX-2 in rat liver cells similarly to neuronal cells [<xref ref-type="bibr" rid="B12">12</xref>] then COX-2 may be degraded in the proteasome by cleavage after large hydrophobic residues.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Effect of epoxomicin on (A) basal and (B) TPA-induced 6-ketoPGF<sub>1&#x003b1; </sub>production and (C) effect of lactacystin on TPA-induced 6-ketoPGF<sub>1&#x003b1; </sub>production. Cells were incubated with the reagents for 6 hours. The analyses were performed with triplicate dishes *- statistically significant <italic>vs </italic>MEM/BSA. **- Statistically significant <italic>vs </italic>TPA.</p></caption><graphic xlink:href="1471-2210-4-15-2"/></fig><p>The amplification of PGI<sub>2 </sub>production (Figs. <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>) after inhibition by epoxomicin could reflect not only stabilization of COX-2 but also an intracellular increase in the concentration of the substrate i.e. the AA that is produced during hydrolysis of the membrane phopholipids by PLase activity [<xref ref-type="bibr" rid="B15">15</xref>]. Extracellular and/or intracellular release of AA will depend, in part, on the localization of the phospholipids in the membrane, e.g. in its inner or outer leaflet [<xref ref-type="bibr" rid="B16">16</xref>]. Release of AA in response to several agonists has been described [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B20">20</xref>].</p><p>The effect of a 2, 4 or 6-h incubation on AA release from rat liver and rat glial cells by 1.0 &#x003bc;M epoxomicin was determined. Only after the 6-h incubation were the differences significant statistically. Regulation of PLase activity by the proteasome pathway appears to be a relatively slow process. After a 6-h incubation, epoxomicin, lactacystin and ZLLL stimulate the release of extracellular AA from rat liver cells (Fig. <xref ref-type="fig" rid="F3">3</xref>) and AA release after TPA-induction (3.7% <italic>vs </italic>13.5% in the presence of 1.0 &#x003bc;M epoxomicin). Epoxomicin also stimulates the release of AA from rat glial, human colon carcinoma and human breast carcinoma cells (Table <xref ref-type="table" rid="T1">1</xref>). The stimulation of AA release from the rat liver cells after incubation with epoxomicin is partially inhibited by pre-incubation of the cells for 2-h with actinomycin (Fig. <xref ref-type="fig" rid="F4">4</xref>) suggesting that a fraction of the PLase is induced. As expected, the inhibition of TPA-induced PGI<sub>2 </sub>production by actinomycin D is complete (Fig. <xref ref-type="fig" rid="F5">5</xref>). Thus, some mechanisms leading to maximum AA release appear to be genomic. The induced PLase activity, probably PLA<sub>2</sub>, could reflect expression of either a secretory or cytosolic PLA<sub>2 </sub>or some combination of both enzymes [<xref ref-type="bibr" rid="B21">21</xref>].</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Dose-response of epoxomicin, lactacystin and ZLLL on AA release from rat liver cells. After incubation for 6 hours. The analyses were performed with triplicate dishes. *- Statistically significant <italic>vs </italic>MEM/BSA.</p></caption><graphic xlink:href="1471-2210-4-15-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Effect of Epoxomicin on AA Release from Rat Glial, Human Colon Carcinoma and Human Breast Carcinoma Cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Cell Type</td><td align="center" colspan="2">% AA Release</td></tr><tr><td></td><td align="center">MEM/BSA control</td><td align="center">With epoxomicin</td></tr></thead><tbody><tr><td align="left">Rat glial (C-6)</td><td align="center">9.0 &#x000b1; 0.07</td><td align="center">11.4 &#x000b1; 0.28</td></tr><tr><td align="left">Human Colon Carcinoma (HT-29)</td><td align="center">7.8 &#x000b1; 0.05</td><td align="center">9.4 &#x000b1; 0.33</td></tr><tr><td align="left">Human Breast Carcinoma (BT-20)</td><td align="center">12.1 &#x000b1; 0.35</td><td align="center">14.2 &#x000b1; 0.31</td></tr></tbody></table><table-wrap-foot><p>Cells were incubated in the presence and absence of 4.5 &#x003bc;M epoxomicin for 6-h, 12-h or 9-h (C-6, HT-29, BT-20 respectively). Analyses were performed with quadruplicate (C-6 and HT-29) or quintuplicate (BT-20) dishes. All values are expressed as Mean &#x000b1; SE (n = 4 or n = 5). All data with epoxomicin are statistically significant <italic>vs </italic>MEM/BSA.</p></table-wrap-foot></table-wrap><fig position="float" id="F4"><label>Figure 4</label><caption><p>Effect of Actinomycin D on AA release from rat liver cells. Cells were preincubated with and without 1.0 &#x003bc;M actinomycin D for 2-h, then incubated in the presence and absence of epoxomicin and actinomycin D for another 6-h. The analyses were performed with triplicate or quadruplicate dishes. *- Statistically significant <italic>vs </italic>epoxomicin in the presence of actinomycin D.</p></caption><graphic xlink:href="1471-2210-4-15-4"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>Effects of actinomycin D on TPA-induced 6-Keto-PGF<sub>1&#x003b1; </sub>production. Cells were preincubated with 1.0 &#x003bc;M actinomycin D for 2-h and then incubated in the presence and absence of 0.6 &#x003bc;M epoxomicin and/or 16.7 &#x003bc;M TPA for another 6-h. The analyses were performed with triplicate dishes. *- Statistically significant <italic>vs </italic>TPA in the absence of actinomycin D. **- Statistically significant <italic>vs </italic>epoxomicin plus TPA in the absence of actinomycin D.</p></caption><graphic xlink:href="1471-2210-4-15-5"/></fig><p>The release of AA from rat liver cells, most likely resulting from PLase activation, is associated with cancer chemoprevention [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>], [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. In addition to its intrinsic biologic activities, AA regulates production of lipoxygenase, cytochrome P-450, and epoxygenase products as well as COX activities. Prostanoid profiles differ with cell type and individual AA metabolites have different pharmacological properties [<xref ref-type="bibr" rid="B15">15</xref>]. COX-2 activity, as measured by PGI<sub>2 </sub>production, is stimulated by proteasome inhibition (Fig. <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>). Thus, some biologic effects of proteasome inhibition, e.g. stimulation of bone formation [<xref ref-type="bibr" rid="B25">25</xref>], may reflect the metabolism of the intracellular AA.</p><p>Inhibition of COX-2 activity is one possible mechanism that has been proposed to prevent colon cancer [<xref ref-type="bibr" rid="B26">26</xref>]. However, rather than inhibiting, tamoxifen and raloxifene, statins and epoxomicin stimulate COX-2 <italic>activity </italic>and AA release from rat liver cells [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. As shown in Table <xref ref-type="table" rid="T1">1</xref>, epoxomicin stimulates AA release from human colon carcinoma, breast carcinoma and rat glial cells. Tamoxifen and simvastatin also stimulate AA release from the human colon carcinoma and human breast carcinoma cells (unpublished data). These drugs have been reported to prevent cancer [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. At least as measured by the COX activity of rat liver cells, tamoxifen, raloxifene, statins and proteasome inhibitors could be preventing cancer by a COX independent mechanism.</p><p>AA resulting from proteasome inhibition has many intrinsic biologic properties [reviewed in [<xref ref-type="bibr" rid="B29">29</xref>]]. Some of these activities may trigger PLase activity. The causal relationship of AA to cancer prevention (if any) is unclear. Production of AA by the tumor-suppressive type-II phospholipase A<sub>2 </sub>(PLA<sub>2</sub>G<sub>2</sub>A) may be related to the cancer prevention [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. It is not surprising that control of PLase activities present an attractive area for cancer prevention studies [<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec sec-type="methods"><title>Methods</title><p>The rat liver (C-9 cell line) and human breast carcinoma (the BT-20 cell line) were purchased from the American Type Culture Collection (Manassas, VA, USA). The rat liver glial cells (C-6 cell line) was obtained from Dr. Elaine Lai of the Department of Biology, Brandeis University and the human colon carcinoma (the HT-29 cell line) was obtained from Dr. Basil Rigas, American Health Foundation, Valhalla, NY, USA. They were maintained in Eagle's minimum essential medium (MEM) supplemented with 10% fetal bovine serum. [<sup>3</sup>H] AA (91.8 Ci/mmol) was obtained from NEN Life Science Products, Inc. (Boston, MA, USA). Epoxomicin, lactacystin and ZLLL were purchased from Biomol (Plymouth Meeting, PA, USA). All other reagents were from Sigma Chemical Co. (St. Louis, MO, USA). Rat liver cells incubating with lactacystin (5.4 &#x003bc;M) or ZLLL (1.0 &#x003bc;M) for 6-h have been tested for viability by a tetrazolium-based assay and found not to be toxic [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>Two days prior to experiments, the rat liver cells were treated with 0.25% trypsin-EDTA and, after addition of minimal essential media (MEM) containing 10% fetal calf serum, the floating cells were seeded onto 35 mm culture dishes. The plating densities varied from 0.1 to 0.5 &#x000d7; 10<sup>5 </sup>cells/35 mm dish. The freshly seeded cultures were incubated for 24-h to allow for cell attachment. After decantation of MEM containing the fetal bovine serum, 1.0 ml fresh MEM containing 10% fetal bovine serum and [<sup>3</sup>H] AA (0.2 &#x003bc;Ci/ml) were added and the cells incubated for another 24-h. The cells were washed 4 times with MEM and incubated for various periods of time with 1.0 ml of MEM containing 1.0 mg BSA/ml (MEM/BSA) and different concentrations of each compound. The culture fluids were then decanted, centrifuged at 2000 &#x000d7; g for 10 min, and 200 &#x003bc;l of the supernate counted for radioactivity. Radioactivity recovered in the washes before the incubation was compared to input radioactivity to calculate the % radioactivity incorporated into the cells [<xref ref-type="bibr" rid="B31">31</xref>]. For PGI<sub>2 </sub>production, 1.0 ml of MEM supplemented with 10% fetal bovine serum, void of [<sup>3</sup>H]AA, was added after the first 24-h incubation. The cells were incubated for another 24-h, washed three times with MEM, then incubated with the compounds in MEM/BSA for various periods of time. The culture fluids were decanted and analyzed for 6-keto-PGF<sub>1&#x003b1;</sub>, the stable hydrolytic product of PGI<sub>2</sub>, by radioimmunoassay [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>The [<sup>3</sup>H] AA release is presented as a percentage of the radioactivity incorporated by the cells. Except for the time-course experiments which used duplicate dishes, three to five culture dishes were used for each experimental point. The data are expressed as mean values &#x000b1; SEM. The data were evaluated statistically by the unpaired <italic>Student's t-test</italic>. A <italic>P </italic>value &#x0003c; 0.05 was considered significant.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>My thanks to Hilda B. Gjika for preparation of the manuscript and to Dr. Armen H. Tashjian, Jr., Department of Genetic and Complex Diseases, Harvard School of Public Health, for his continuing interest in these studies.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>AF</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Proteasome inhibitors: from research tools to drug candidates</article-title><source>Chem Biol</source><year>2001</year><volume>8</volume><fpage>739</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">11514224</pub-id><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00056-4</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>BS</given-names></name></person-group><article-title>The proteasome &#x02013; an emerging therapeutic target in cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>2597</fpage><lpage>2598</lpage><pub-id pub-id-type="pmid">12826633</pub-id><pub-id pub-id-type="doi">10.1056/NEJMp030092</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name></person-group><article-title>Potential for proteasome inhibition in the treatment of cancer</article-title><source>Drug Discov Today</source><year>2003</year><volume>8</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">12654543</pub-id><pub-id pub-id-type="doi">10.1016/S1359-6446(03)02647-3</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>M</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><name><surname>Kaneta</surname><given-names>K</given-names></name><name><surname>Toda</surname><given-names>S</given-names></name><name><surname>Nishiyama</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><name><surname>Oki</surname><given-names>T</given-names></name></person-group><article-title>Epoxomicin, a new antitumor agent of microbial origin</article-title><source>J Antibiot (Tokyo</source><year>1992</year><volume>45</volume><fpage>1746</fpage><lpage>1752</lpage><pub-id pub-id-type="pmid">1468981</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Mohan</surname><given-names>R</given-names></name><name><surname>Kwok</surname><given-names>BH</given-names></name><name><surname>Elofsson</surname><given-names>M</given-names></name><name><surname>Sin</surname><given-names>N</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name></person-group><article-title>Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>10403</fpage><lpage>10408</lpage><pub-id pub-id-type="pmid">10468620</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.18.10403</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostrowska</surname><given-names>H</given-names></name><name><surname>Wojcik</surname><given-names>C</given-names></name><name><surname>Omura</surname><given-names>S</given-names></name><name><surname>Worowski</surname><given-names>K</given-names></name></person-group><article-title>Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme</article-title><source>Biochem Biophys Res Commun</source><year>1997</year><volume>234</volume><fpage>729</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">9175783</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1997.6434</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellgren</surname><given-names>RL</given-names></name></person-group><article-title>Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>29899</fpage><lpage>29903</lpage><pub-id pub-id-type="pmid">9368065</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.47.29899</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogyo</surname><given-names>M</given-names></name><name><surname>McMaster</surname><given-names>JS</given-names></name><name><surname>Gaczynska</surname><given-names>M</given-names></name><name><surname>Tortorella</surname><given-names>D</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name><name><surname>Ploegh</surname><given-names>H</given-names></name></person-group><article-title>Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>6629</fpage><lpage>6634</lpage><pub-id pub-id-type="pmid">9192616</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.13.6629</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bromme</surname><given-names>D</given-names></name><name><surname>Klaus</surname><given-names>JL</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Rasnick</surname><given-names>D</given-names></name><name><surname>Palmer</surname><given-names>JT</given-names></name></person-group><article-title>Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L</article-title><source>Biochem J</source><year>1996</year><volume>315</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">8670136</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Proteolysis negatively regulates agonist-stimulated arachidonic acid metabolism</article-title><source>Cell Signal</source><year>1998</year><volume>10</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">9794247</pub-id><pub-id pub-id-type="doi">10.1016/S0898-6568(98)00008-4</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Lactacystin stimulates arachidonic acid metabolism in rat liver cells: effects of cell density on arachidonic acid release, PGI2 production and cyclooxygenase activity</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2000</year><volume>63</volume><fpage>371</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">11133174</pub-id><pub-id pub-id-type="doi">10.1054/plef.2000.0230</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rockwell</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Magnusson</surname><given-names>R</given-names></name><name><surname>Figueiredo-Pereira</surname><given-names>ME</given-names></name></person-group><article-title>Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2)</article-title><source>Arch Biochem Biophys</source><year>2000</year><volume>374</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">10666314</pub-id><pub-id pub-id-type="doi">10.1006/abbi.1999.1646</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rigas</surname><given-names>A</given-names></name><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Arachidonic acid metabolism by rat liver cells (the C-9 cell line)</article-title><source>J Pharmacol Exp Ther</source><year>1984</year><volume>231</volume><fpage>230</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">6436471</pub-id></citation></ref><ref id="B14"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Tamoxifen and the raloxifene analog LY117018: their effects on arachidonic acid release from cell in culture and on prostaglandin I2 production by rat liver cells</article-title><source>BMC Cancer</source><year>2004</year></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>WL</given-names></name></person-group><article-title>The eicosanoids and their biochemical mechanisms of action</article-title><source>Biochem J</source><year>1989</year><volume>259</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">2655580</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edidin</surname><given-names>M</given-names></name></person-group><article-title>The state of lipid rafts: from model membranes to cells</article-title><source>Annu Rev Biophys Biomol Struct</source><year>2003</year><volume>32</volume><fpage>257</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12543707</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biophys.32.110601.142439</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Does the release of arachidonic acid from cells play a role in cancer chemoprevention?</article-title><source>FASEB J</source><year>2003</year><volume>17</volume><fpage>800</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">12724337</pub-id><pub-id pub-id-type="doi">10.1096/fj.02-0906hyp</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism</article-title><source>BMC Cancer</source><year>2003</year><volume>3</volume><fpage>24</fpage><pub-id pub-id-type="pmid">14498998</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-3-24</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells</article-title><source>Lipids Health Dis</source><year>2003</year><volume>2</volume><fpage>1</fpage><pub-id pub-id-type="pmid">12689340</pub-id><pub-id pub-id-type="doi">10.1186/1476-511X-2-1</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Nuclear receptor agonists stimulate release of arachidonic acid from rat liver cells</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2002</year><volume>67</volume><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">12468267</pub-id><pub-id pub-id-type="doi">10.1054/plef.2002.0456</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>BL</given-names></name><name><surname>Arm</surname><given-names>JP</given-names></name></person-group><article-title>Phospholipase A(2)</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2003</year><volume>69</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">12895591</pub-id><pub-id pub-id-type="doi">10.1016/S0952-3278(03)00069-3</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Praml</surname><given-names>C</given-names></name><name><surname>Amler</surname><given-names>LC</given-names></name><name><surname>Dihlmann</surname><given-names>S</given-names></name><name><surname>Finke</surname><given-names>LH</given-names></name><name><surname>Schlag</surname><given-names>P</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>2009</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">9788445</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1202121</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cormier</surname><given-names>RT</given-names></name><name><surname>Hong</surname><given-names>KH</given-names></name><name><surname>Halberg</surname><given-names>RB</given-names></name><name><surname>Hawkins</surname><given-names>TL</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Mulherkar</surname><given-names>R</given-names></name><name><surname>Dove</surname><given-names>WF</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><article-title>Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis</article-title><source>Nature Genetics</source><year>1997</year><volume>17</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">9288104</pub-id><pub-id pub-id-type="doi">10.1038/ng0997-88</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacPhee</surname><given-names>M</given-names></name><name><surname>Chepenik</surname><given-names>KP</given-names></name><name><surname>Liddell</surname><given-names>RA</given-names></name><name><surname>Nelson</surname><given-names>KK</given-names></name><name><surname>Siracusa</surname><given-names>LD</given-names></name><name><surname>Buchberg</surname><given-names>AM</given-names></name></person-group><article-title>The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia</article-title><source>Cell</source><year>1995</year><volume>81</volume><fpage>957</fpage><lpage>966</lpage><pub-id pub-id-type="pmid">7781071</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(95)90015-2</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>IR</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Gutierrez</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Escobedo</surname><given-names>A</given-names></name><name><surname>Rossini</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>SE</given-names></name><name><surname>Gallwitz</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Crews</surname><given-names>CM</given-names></name><name><surname>Mundy</surname><given-names>GR</given-names></name></person-group><article-title>Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>1771</fpage><lpage>1782</lpage><pub-id pub-id-type="pmid">12782679</pub-id><pub-id pub-id-type="doi">10.1172/JCI200316198</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subbaramaiah</surname><given-names>K</given-names></name><name><surname>Dannenberg</surname><given-names>AJ</given-names></name></person-group><article-title>Cyclooxygenase 2: a molecular target for cancer prevention and treatment</article-title><source>Trends Pharmacol Sci</source><year>2003</year><volume>24</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">12559775</pub-id><pub-id pub-id-type="doi">10.1016/S0165-6147(02)00043-3</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>VC</given-names></name><name><surname>Morrow</surname><given-names>M</given-names></name></person-group><article-title>Tamoxifen, raloxifene, and the prevention of breast cancer</article-title><source>Endocr Rev</source><year>1999</year><volume>20</volume><fpage>253</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">10368771</pub-id><pub-id pub-id-type="doi">10.1210/er.20.3.253</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brower</surname><given-names>V</given-names></name></person-group><article-title>Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins</article-title><source>J Natl Cancer Inst</source><year>2003</year><volume>95</volume><fpage>844</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">12813163</pub-id><pub-id pub-id-type="doi">10.1093/jnci/95.12.844</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brash</surname><given-names>AR.</given-names></name></person-group><article-title>Arachidonic acid as a bioactive molecule</article-title><source>J Clin Invest</source><year>2001</year><volume>107</volume><fpage>1339</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">11390413</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laye</surname><given-names>JP</given-names></name><name><surname>Gill</surname><given-names>JH</given-names></name></person-group><article-title>Phospholipase A2 expression in tumours: a target for therapeutic intervention?</article-title><source>Drug Discov Today</source><year>2003</year><volume>8</volume><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">12927514</pub-id><pub-id pub-id-type="doi">10.1016/S1359-6446(03)02754-5</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><article-title>Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2001</year><volume>65</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">11487305</pub-id><pub-id pub-id-type="doi">10.1054/plef.2001.0284</pub-id></citation></ref><ref id="B32"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>L</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rose NR, Friedman H, Fahey JL</surname></name></person-group><source>Measurement of arachidonic acid metabolites by radioimmunoassay. Manual of Clinical Laboratory Immunology</source><year>1986</year><edition>3</edition><publisher-name>Washington DC: American Society for Microbiology</publisher-name><fpage>685</fpage><lpage>691</lpage></citation></ref></ref-list></back></article>



